LABT LABT
Company Profile ↓Company Overview
LABT (LABT) is a publicly traded company listed on with a market capitalization of $3.23M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -97.33% |
| 6 Months: | - |
| 3 Months: | -92.55% |
| 1 Month: | -3.35% |
- Price vs 50-DMABelow
- RSI (14)28.91 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 862.18K | 542.61K | 1.88M | 712.06K | 886.75K |
| Operating Income | -862.18K | -542.61K | -1.88M | -712.06K | -886.75K |
| EBITDA | -825.03K | -508.60K | -1.87M | -676.82K | -854.58K |
| Interest Expense | 0 | 1.31K | 37.81K | 37.81K | 38.22K |
| Pretax Income | -854.54K | -539.62K | -1.91M | -744.92K | -923.29K |
| Tax Provision | - | - | - | - | - |
| Net Income | -854.54K | -539.62K | -1.91M | -744.92K | -923.29K |
| Diluted EPS | - | -1.50 | -1.37 | - | -2.00 |
| R&D Expense | - | 169.70K | - | - | 182.15K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 8.64M | 4.03M | 3.77M |
| Operating Income | -8.64M | -4.03M | -3.77M |
| EBITDA | -8.15M | -4.73M | -3.63M |
| Interest Expense | 10.00K | 5.00K | 100.88K |
| Pretax Income | -8.28M | -4.86M | -3.85M |
| Tax Provision | - | - | - |
| Net Income | -8.28M | -4.86M | -3.85M |
| Diluted EPS | -11.84 | -6.94 | -2.76 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 6.89M | 1.07M | 481.60K |
| Current Assets | 6.48M | 773.98K | 305.39K |
| Cash & Equivalents | 2.53M | 681.10K | 236.40K |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | 2.34M | 660.97K | 2.45M |
| Current Liabilities | 2.06M | 500.63K | 2.41M |
| Long Term Debt | - | - | - |
| Total Debt | 578.88K | 272.86K | 1.66M |
| Total Equity | 4.56M | 409.61K | -1.96M |
| Shares Outstanding | 1.39M | 1.39M | 1.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -6.82M | -5.72M | -1.94M |
| Investing Cash Flow | -3.78M | 3.92M | 0 |
| Financing Cash Flow | 0 | -50.00K | 1.50M |
| Capital Expenditure | - | -1.85K | - |
| Free Cash Flow | -6.82M | -5.73M | -1.94M |
| Net Change in Cash | -10.60M | -1.85M | -444.70K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -181.7% | -1,185.4% | 195.9% |
| ROCE % | -178.8% | -706.5% | 196.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LABT
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® clas…
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® clas…
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics
NASDAQ: LABT David Bautz, PhD: Welcome to our next episode in our CEO Chat series. My name is David Bautz. I'm a senior biotechnology analyst here at Zacks Small Cap Research . Joining me today is Dr. Kelvin Cooper, CEO of Lakewood-Amedex B…
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® clas…
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available…
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® clas…
LABT — Frequently Asked Questions
What is the current share price of LABT?
As of 2026-08-05 17:25 PDT, LABT trades at $2.31 on NASDAQ/NYSE. Its 52-week range is $1.85 to $86.50.
What is the market capitalisation of LABT?
LABT has a market capitalisation of $3.23M on NASDAQ/NYSE.
What is the P/E ratio of LABT?
LABT trades at a trailing price-to-earnings (P/E) ratio of -0.84. Its price-to-book (P/B) ratio is -1.64.
Is LABT a good stock to buy?
This page provides a data-driven analysis of LABT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.